Bitopertin met every primary and secondary endpoint in APOLLO, eight months after the FDA turned down Disc’s first application. Disc Medicine (NASDAQ: IRON) shares jumped…
October 16, 2026
PRISM Mid-Day Movers: MedTech and Biotech are Today’s Leaders.
CytoSorbents (NASDAQ: CTSO) rose 14.71% to $3.51 by mid-day, with no new company announcement behind the move. The gain follows recent CytoSorb data presentations at…
Key Points Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026. He brings more than 20 years of…
Key Points The FDA has cleared Anavex to proceed with a U.S. clinical study of blarcamesine in Fragile X syndrome. The planned Phase 2a trial…
Adlai Nortye Group Ltd. (NASDAQ: ANL), a clinical-stage biotechnology company developing RAS pathway and immunotherapy treatments for cancer, announced on October 15, 2026 clinical trial…
October 15, 2026
Vivos Signs $12 Million Stock Deal for Stake in SOD Sciences and Joint Ownership of Experimental Test
Key Points Vivos Therapeutics agreed to acquire an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its proprietary early-warning test. Vivos will…
Key Points A randomized trial found better preservation of erectile function and bladder control with TULSA than with robotic prostate surgery at six months. Additional…
Key Points Pulse Biosciences partnered with the Clayman Thyroid Center in Tampa for commercial use and clinical research involving its nPulse Vybrance System. The center…
October 14, 2026
Rhythm Launches IMCIVREE in Japan, Bringing the First Approved Treatment for Acquired Hypothalamic Obesity
Key Points Rhythm Pharmaceuticals has commercially launched IMCIVREE in Japan for acquired hypothalamic obesity. The launch follows regulatory approval in August and inclusion on Japan’s…
October 14, 2026
Arrowhead’s Under-the-Skin Tau Data Puts Brain Delivery in Focus for Alzheimer’s Stocks
Arrowhead cut spinal fluid tau by a mean of 73% without a spinal injection. Denali, Voyager and Annovis are testing other routes to lower tau….
October 13, 2026
Immuron’s Travelan Study Signals Potential for Better Protection Against Travelers’ Diarrhea
Key Points Immuron’s Phase 2 study of once-daily Travelan has been published in Scientific Reports, a journal in the Nature portfolio. The study reported a…
October 13, 2026
BrainsWay Expands Insurance Coverage for Accelerated Deep TMS to Over 70 Million U.S. Lives
Key Points BrainsWay says favorable U.S. insurance policies for its SWIFT Accelerated Deep TMS protocol now cover more than 70 million lives. The expansion creates…